实用肿瘤学杂志 ›› 2010, Vol. 24 ›› Issue (1): 48-52.doi: 10.3969/j.issn.1002-3070.2010.01.012

• 论著 • 上一篇    下一篇

局部晚期非小细胞肺癌不同放化疗模式的临床研究

徐建宇, 徐向英, 许庆勇, 胡松柳, 刘珊珊, 卢姗   

  1. 哈尔滨医科大学附属肿瘤医院放疗科(哈尔滨 150081)
  • 收稿日期:2010-01-04 出版日期:2010-02-28 发布日期:2015-01-23
  • 通讯作者: 徐向英,E-mail:xuxxyy@sohu.com
  • 作者简介:徐建宇,男,(1982-),硕士,住院医师,从事肺癌的放疗、化疗研究

Clinical research on differential chemoradiotherapy pattern in treatment of locally advanced non-small cell lung cancer

XU Jianyu , XU Xiangying, XU Qingyong, HU Songliu, LIU Shanshan, LU Shan   

  1. Department of Radiation Oncology,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081
  • Received:2010-01-04 Online:2010-02-28 Published:2015-01-23

摘要: 目的 探讨三维适形放疗(3DCRT)、序贯化疗的不同模式治疗局部晚期非小细胞肺癌(LANSCLC)的临床疗效。方法 2001年7月-2006年12月,83例符合入组标准的LANSCLC患者纳入本研究,根据放疗的参与时机分为三组,1组:诱导化疗1-2周期+放疗组;2组:诱导化疗3-4周期+放疗组;3组:诱导化疗5-6周期+放疗组。放射治疗均采用3DCRT技术,化疗采用以顺铂为主的联合化疗方案,对比观察三组患者的近期疗效,1、2年生存率,中位生存期和毒副反应。结果 三组患者的总有效率分别为89.3%、78.1%和68.5%(P>0.05)。三组患者的1、2年生存率分别为75.00%、67.86%、51.16%和49.01%、44.44%、31.97%,中位生存期分别为21个月、18个月和16个月(P<0.05)。三组的毒副反应发生率无显著性差异。全组患者的1、2年生存率为64.87%和41.56%,中位生存期20个月。ⅢA和ⅢB期患者的中位生存期分别为21个月和16个月(P<0.05)。结论 3DCRT联合应用序贯化疗是安全和有效的,两者的联合应用能够提高LANSCLC的临床疗效。在序贯放化疗模式中,各组研究结果显示放疗的尽早参与能够提高LANSCLC患者的临床疗效,诱导化疗次数以1-2周期为宜,增加诱导化疗的次数没有带来生存益处。

Abstract: Objective To evaluate the outcome of locally advanced non-small cell lung cancer treated with radiotherapy and chemotherapy.Methods From July 2001 to December 2006,83 patients with locally advanced non-small cell lung cancer were enrolled.Three groups were divided based on time and sequence of radiotherapy and chemotherapy.All patients used three dimensional conformal radiation therapy and cisplatin based chemotherapy.The short-term response and 1-year,2-year survival rates,median survival time and toxicity in three groups were compared.Results The overall response in three groups were 89.3%,78.1% and 68.5%(P>0.05)respectively.The median survival time were 21 months,18 months and 16 months,respectively,The 1-,2-year survival rate were 75%,67.86%,51.16% and 49.01%,44.44%,31.97%(P<0.05)respectively for three groups.And the differences of toxicity rates for three groups were not statistically significant.Conclusion Induction chemotherapy followed by three dimensional conformal radiation therapy was efficacy and safety.The sequential chemoradiotherapy improved the overall survival of locally advanced non-small cell lung cancer.The output indicated early irradiation with chemoradiotherapy is superior to late irradiation.Induction chemotherapy is optimization for one or two cycles.

中图分类号: